Overview

Transurethral Resection of Bladder Tumor (TURBT) Combined With Adjuvant Intravenous GC Chemotherapy for Non-muscle-invasive Bladder Cancer

Status:
Unknown status

Trial end date:
2020-12-01

Target enrollment:
0

Participant gender:
All

Summary

It is still a challenge for urologic surgeon to prevent the post transurethral resection of bladder tumor (TURBT) recurrence of moderate-high risk non-muscle invasive bladder tumor. Adjuvant chemotherapy is a standard treatment for local progressive bladder tumor, which contains mainstream GC treatment scheme. It is common to observe clinically moderate-high risk NMIBC recurrence after routine intravesical instillation.Systematic chemotherapy can eliminate remained tumor cells especially those from mucosa basal cells so as to improve the prognosis of patients. Our clinical trial aims to investigate whether the utilization of combination of GC treatment scheme and epirubicin instillation would decrease the recurrence of moderate-high risk NMIBC.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

The First Affiliated Hospital with Nanjing Medical University

Treatments:

Cisplatin
Epirubicin
Gemcitabine

Criteria

Inclusion Criteria:

1. moderate-high risk non-muscle invasive bladder cancer patients: Multiple,recurrent,
II-III grade, tumor diameter>3cm, invasive to submucosa, associated with carcinoma in
situ.

2. Normal liver and renal function.

Exclusion Criteria:

1. Liver and renal function deficiency (GFR<60ml/min*kg, ALT、AST>1.5*normal), lung
function deficiency, heart failure, acute myocardial infarction, severe infection and
trauma, major surgery and clinical hypotension and anaerobic conditions.

2. Attending other drug experiments.

3. Performance status, Zubrod-ECOG-WHO, ZPS≥2.

4. Pregnant.

5. Bone marrow transplantation, severe leukopenia, associated with severe infection or
injury.